Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations by Fan, Hong-Qi et al.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Prognostic value of isolated nocturnal hypertension on
ambulatory measurement in 8711 individuals from
10 populations
Hong-Qi Fana, Yan Lia, Lutgarde Thijsb, Tine W. Hansenc, Jose´ Boggiad,
Masahiro Kikuyae, Kristina Bjo¨rklund-Bodega˚rdf, Tom Richartb,g, Takayoshi
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Sofia Malyutinal, Edoardo Casigliak, Yuri Nikitinl, Lars Lindf, Edgardo
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Jiguang Wanga and Jan A. Staessenb,g, on behalf of the International Database
on Ambulatory blood pressure in relation to Cardiovascular Outcomes
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Background We and other investigators previously
reported that isolated nocturnal hypertension on
ambulatory measurement (INH) clustered with
cardiovascular risk factors and was associated with
intermediate target organ damage. We investigated
whether INH might also predict hard cardiovascular
endpoints.
Methods and results We monitored blood pressure (BP)
throughout the day and followed health outcomes in 8711
individuals randomly recruited from 10 populations (mean
age 54.8 years, 47.0% women). Of these, 577 untreated
individuals had INH (daytime BP <135/85mmHg and
night-time BP >–120/70mmHg) and 994 untreated
individuals had isolated daytime hypertension on
ambulatory measurement (IDH; daytime BP >–135/
85mmHg and night-time BP <120/70mmHg). During
follow-up (median 10.7 years), 1284 deaths (501
cardiovascular) occurred and 1109 participants
experienced a fatal or nonfatal cardiovascular event. In
multivariable-adjusted analyses, compared with
normotension (nU 3837), INH was associated with a
higher risk of total mortality (hazard ratio 1.29, PU 0.045)
and all cardiovascular events (hazard ratio 1.38,
PU 0.037). IDH was associated with increases in all
cardiovascular events (hazard ratio 1.46, PU 0.0019) and
cardiac endpoints (hazard ratio 1.53, PU0.0061).
Of 577 patients with INH, 457 were normotensive
(<140/90mmHg) on office BP measurement. Hazard
ratios associated with INH with additional adjustment for
office BP were 1.31 (PU 0.039) and 1.38 (PU 0.044) for
total mortality and all cardiovascular events, respectively.
After exclusion of patients with office hypertension,
these hazard ratios were 1.17 (PU 0.31) and 1.48
(PU0.034).
Conclusion INH predicts cardiovascular outcome in
patients who are normotensive on office or on ambulatory
daytime BP measurement. J Hypertens 28:2036–2045 Q
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Introduction
In 2007, we described isolated nocturnal hypertension
on ambulatory measurement (INH) as a potentially
novel clinical entity [1]. Among 677 Chinese randomly
recruited from a rural area, 74 (10.9%) had, on ambulatory
monitoring, an elevated night-time blood pressure (BP)
(120/70mmHg) in the presence of a normal daytime BP
(<135/85mmHg) [1]. Of the 74 patients, only four
(5.4%) had hypertension on office BP measurement
(140/90mmHg), which highlighted that automated
BP measurement during sleep was required to diagnose
INH. Along similar lines, Hoshide et al. [2] reported an
elevated night-time BP (120/75mmHg) in the presence
of a normal self-measured home BP (<135/85mmHg)
in 17 (10.3%) of 165 community-dwelling individuals.
Wijkman et al. [3] also observed nocturnal hyperten-
sion (120/70mmHg) but a normal clinic BP (<130/
80mmHg) among 30 (7.2%) of 414 type-2 diabetic
patients. In analyses of the International Database of
the Ambulatory Blood Pressure [4], we noticed that
the prevalence of INH was higher among South Africans
of black ancestry (10.2%) and Japanese (10.9%) than in
Western (6.0%) and Eastern (7.9%) Europeans [1].
In previous studies, INH was associated with clustering
of cardiovascular risk factors [1], thickening of the carotid
intima–media [2], left ventricular remodeling [2], and
increased arterial stiffness, as reflected by aortic pulse
wave velocity [1,3], the central and peripheral augmenta-
tion indexes [1], and the ambulatory arterial stiffness
index [1]. However, the major question whether INH
might also predict a worse cardiovascular outcome in
terms of hard endpoints remains unanswered. To address
this issue, we analyzed the International Database of
Ambulatory blood pressure in relation to Cardiovascular
Outcome (IDACO) [5–8].
Methods
Study population
As described in detail elsewhere [5–8], we constructed the
IDACO database. Studies were eligible for inclusion, if
they involved a random population sample, if baseline
information on ambulatory BP and cardiovascular risk
factors was available, and if the subsequent follow-up
included fatal and nonfatal outcomes. Of 13 studies
[9–19], we excluded two [18,19] because at the time of
writing of this manuscript follow-up had not yet been
organized [19] or because follow-up did not include non-
fatal events [18]. All studies received ethical approval and
have been reported in peer-reviewed publications.
At the time of writing of this report, the IDACO database
included 11 785 individuals enrolled in prospective popu-
lation studies at 11 centers [9–17]. For the present
analysis, we selected studies in which all the necessary
data, including ambulatory BPs, biochemical measure-
ments, and outcome data, were available, leaving 10
cohorts [10–17] and 10 805 individuals for possible
analysis. In line with previous reports [7–8], we excluded
250 participants because they were below 18 years, and
1844 participants because they had fewer than 10 daytime
or five night-time BP readings. The 8711 analyzed
participants included: 1127 from Noorderkempen,
Belgium [10]; 351 from the JingNing county, China
[15]; 165 from Pilsen, the Czech Republic [14]; 2142
from Copenhagen, Denmark [16]; 310 from Padova, Italy
[14]; 1526 from Ohasama, Japan [13]; 308 from Krako´w,
Poland [14]; 244 from Novosibirsk, the Russian Federa-
tion [12,14]; 1100 older men from Uppsala, Sweden [17];
and 1438 individuals fromMontevideo, Uruguay [11]. All
participants gave informed written consent.
Blood pressure measurements
Conventional BP was measured by trained observers with
a mercury sphygmomanometer [10,12,14–17], with vali-
dated auscultatory [13] (USM-700F; UEDA Electronic
Works, Tokyo, Japan) or oscillometric [11] (OMRON
HEM-705CP; Omron Corporation, Tokyo, Japan)
devices, using the appropriate cuff size, with the partici-
pants in the sitting [10–16] or supine [17] position.
Conventional BP was the average of two consecutive
readings obtained either at the participants’ homes
[10–12,14,15] or at an examination center [13,16,17].
Hypertension was a conventional SBP of at least
140mmHg or DBP of 90mmHg at a single visit or use
of antihypertensive drugs [20].
We programmed portable monitors to obtain ambulatory
BP readings at 30-min intervals throughout the whole day
[13] or at intervals ranging from 15 [16] to 30 [17] minutes
during daytime and from 30 [16] to 60 [17] minutes at
night. The devices implemented an auscultatory algor-
ithm (Accutracker II; Suntech Medical Instruments,
North Carolina, USA) in Uppsala [17] or an oscillometric
technique (SpaceLabs 90202 and 90207, SpaceLabs
Medical Inc., Redmond, Washington, USA; Takeda
TM-2421, A&D Instruments, Tokyo, Japan; and ABPM
630, Nippon Colin, Komaki, Japan) in the other cohorts
[10–16].
The same Statistical Analysis System (SAS; SAS Insti-
tute, Cary, North Carolina, USA) macro processed all
ambulatory recordings, which generally stayed unedited.
The Ohasama recordings were edited sparsely according
to previously published criteria [21].While accounting for
the daily pattern of activities of the participants, we
defined daytime as the interval from 1000 to 2000 h in
Europeans [10,12,14,16,17] and South Americans [11],
and from 0800 to 1800 h in Asians [13,15]. The corre-
sponding night-time intervals ranged from midnight to
0600 h [10–12,14,16,17] and from 2200 to 0400 h [13,15],
respectively. These fixed time intervals eliminate the
transition periods in the morning and evening when BP
changes rapidly, resulting in daytime and night-time BP
levels that are within 1–2mmHg of the awake and asleep
levels [15,22]. Within individual participants, we
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weighted the means of the ambulatory BP by the interval
between readings.
In line with published diagnostic thresholds of ambulat-
ory normotension [23], we defined nocturnal hyperten-
sion as a night-time BP of at least 120mmHg SBP or
70mmHg DBP. Daytime hypertension was a diurnal BP
of at least 135mmHg SBP or 85mmHg DBP. On the
basis of these cutoff limits of the ambulatory BP and
treatment status, we classified patients into four groups:
untreated individuals, who were normotensive during
daytime and night-time; untreated individuals with iso-
lated daytime hypertension on ambulatory measurement
(IDH); untreated individuals with INH; and patients
with hypertension sustained during daytime and night-
time or on treatment for hypertension irrespective of their
BP level during daytime or night-time.
Other measurements
We used the questionnaires originally administered in
each cohort to obtain information on each participant’s
medical history, and smoking and drinking habits. BMI
was body weight in kilograms divided by height in meters
squared. We measured serum cholesterol and blood glu-
cose by automated enzymatic methods. Diabetes mellitus
was the use of antidiabetic drugs, a fasting blood glucose
concentration of at least 7.0mmol/l [10–17], a random
blood glucose concentration of at least 11.1mmol/l
[10,13,15], a self-reported diagnosis [10,11,13], or diabetes
documented in practice or hospital records [11].
Ascertainment of events
We ascertained vital status and the incidence of fatal and
nonfatal diseases from the appropriate sources in each
country, as described in previous publications [5–8].
Fatal and nonfatal stroke did not include transient
ischemic attack. Coronary events encompassed death
from ischemic heart disease, sudden death, nonfatal
myocardial infarction (MI), and coronary revasculari-
zation. Cardiac events comprised coronary endpoints
and fatal and nonfatal heart failure. The composite car-
diovascular endpoint included all aforementioned end-
points and cardiovascular mortality. In all outcome
analyses, we only considered the first event within
each category.
Statistical methods
For database management and statistical analysis, we
used SAS software, version 9.1.3 (SAS Institute). For
comparison of means and proportions, we applied the
large-sample z-test and the x2-statistic, respectively.
After stratification for cohort and sex, we interpolated
missing values of BMI (n¼ 17) and total serum choles-
terol (n¼ 121) from the regression slope on age. In
individuals with unknown drinking (n¼ 786) or smoking
habits (n¼ 39), or with unknown status of diabetes
(n¼ 3), we set the design variable to the cohort and
sex-specific mean of the codes (0,1). Statistical signifi-
cance was an a-level of less than 0.05 on two-sided tests.
We first tabulated the incidence of endpoints by BP
status on ambulatory measurement. We reported crude
rates and rates standardized by the direct method for
cohort, sex, and age (40, 40–60, and 60 years). We
used Kaplan–Meier survival function estimates, plotted
according to current recommendations [24], and the log-
rank test to compare incidence rates by BP group. We
used Cox regressions to compute hazard ratios associated
with each ambulatory hypertensive group relative to the
normotensive group for mortality and for fatal and non-
fatal outcomes combined. The hazard ratios were strati-
fied for cohort and adjusted for sex, age (treated as a
continuous variable), BMI (continuous), smoking (0, 1)
and drinking (0, 1), serum cholesterol (continuous),
history of cardiovascular disease (0, 1), and diabetes
mellitus (0, 1). While stratifying for cohort, we pooled
the cohorts recruited in the framework of the European
Project onGenes inHypertension [14].We tested hetero-
geneity in the hazard ratios across subgroups by introdu-
cing the appropriate interaction term in the Cox models.
To test the prognostic significance of nocturnal BP in
individuals with normal daytime BP on office or on
ambulatory BP measurement, we modeled the pro-
bability of the 10-year incidence of total mortality and
fatal and nonfatal cardiovascular events using theWeibull
distribution for time-failure data.
Results
Baseline characteristics
The study population consisted of 5396 Europeans
(61.9%), 1877 Asians (21.6%), and 1438 South Americans
(16.5%). The 8711 participants included 4096 women
(47.0%) and 3532 patients with office hypertension
(40.6%), of whom 1899 (53.8%) were taking BP-lowering
drugs. Mean (SD) age was 54.8 15.1 years. At enroll-
ment, 2491 participants (28.6%) were current smokers
and 4126 (47.4%) reported intake of alcohol.
Of 8711 participants, 3837 (44.1%) were normotensive
during daytime and night-time, 994 (11.4%) had IDH,
577 (6.6%) had INH, and 3303 (37.9%) had sustained
hypertension. Table 1 shows the baseline characteristics
of the participants according to their BP status. The
prevalence of INH was significantly higher (P< 0.05)
in South Americans (9.4%) than in Asians (7.2%) and
Europeans (5.7%). Compared with individuals with
ambulatory normotension, patients with INH were older,
more likely to be men, and more frequently reported
alcohol intake. They also had a higher BMI, a faster pulse
rate at night, and higher serum cholesterol and blood
glucose. The 577 patients with INH included 150
(26.0%) with isolated systolic hypertension, 233
(40.4%) with isolated diastolic hypertension, and 194
(33.6%) with systolic and diastolic hypertension. Of the
2038 Journal of Hypertension 2010, Vol 28 No 10
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577 patients with INH, only 120 (20.8%) were diagnosed
as being hypertensive on conventional BP measurement.
Incidence of events
In the overall study population,median follow-upwas 10.7
years (5th to 95th percentile interval 2.5–15.4 years).
Across cohorts, median follow-up ranged from 2.5 years
(5th to 95th percentile interval 2.3–2.6 years) in JingNing
to 13.3 years (5th–95th percentile interval 4.7–16.3 years)
in Noorderkempen. During 87 203 person-years of follow-
up, 1284 participants died (14.7 per 1000 person-years) and
1109 experienced a fatal or nonfatal cardiovascular com-
plication (13.2 per 1000 person-years). Mortality included
501 cardiovascular and 742 noncardiovascular deaths and
41 deaths from unknown cause (Table 2). Considering
cause-specific first cardiovascular events, the incidence of
fatal and nonfatal stroke amounted to 145 and 391, respec-
tively. Cardiac events consisted of 176 fatal and 442
nonfatal events, including 76 fatal and 214 nonfatal cases
of acute MI, 32 deaths from ischemic heart disease, 28
sudden deaths, 40 fatal and 171 nonfatal cases of heart
failure, and 57 cases of surgical or percutaneous coronary
revascularization.
Risk associated with subtypes of ambulatory
hypertension
Table 2 shows the crude and cohort, sex, and age-
standardized rates of mortality and combined fatal and
nonfatal events by subtypes of ambulatory hypertension.
The Kaplan–Meier survival function estimates for total
mortality and for all fatal combined with nonfatal cardio-
vascular events according to BP classification appear in
Fig. 1. Compared with normotensive individuals, patients
with IDH, INH, or sustained hypertension had a signi-
ficantly higher (P< 0.05) incidence of mortality and
morbidity (Table 2).
Table 3 provides unadjusted and adjusted hazard
ratios associated with the three categories of ambulatory
hypertension relative to the normotensive control
group. With cumulative adjustments applied for cohort,
sex, age, BMI, smoking and drinking, serum cholesterol,
diabetes, and history of cardiovascular disease, INH was
associated with an increased risk for total mortality
(hazard ratio 1.29, P¼ 0.045) and all cardiovascular
events (hazard ratio 1.38, P¼ 0.037). The hazard ratios
for cardiovascular mortality (1.30, P¼ 0.29), cardiac
events (1.41, P¼ 0.096), and stroke (1.21, P¼ 0.46)
were of similar magnitude but did not reach statistical
significance because of the relatively low number of
events for these endpoints. With similar adjustments
applied, IDH was associated with significant increases
in all cardiovascular events (hazard ratio 1.46,P¼ 0.0019)
and cardiac endpoints (hazard ratio 1.53, P¼ 0.0061), but
not total mortality (hazard ratio 1.07, P¼ 0.56), cardio-
vascular mortality (hazard ratio 1.38, P¼ 0.091), and
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Table 1 Baseline characteristics of participants
Characteristics Normotension Isolated nocturnal hypertension Isolated daytime hypertension Sustained hypertension
Number of participants 3837 577 994 3303
European 2303 (60.0) 307 (53.2)y 747 (75.2)y 2039 (61.7)
Asian 814 (21.2) 135 (23.4) 129 (12.9)y 799 (24.2)y
South American 720 (18.8) 135 (23.4)y 118 (11.9)y 465 (14.1)z
Women 2167 (56.5) 224 (38.8)z 353 (35.5)z 1352 (40.9)z
Smokers 1131 (29.5) 179 (31.0) 331 (33.3)M 850 (25.7)y
Drinking alcohol 1602 (41.8) 274 (47.5)y 581 (58.5)z 1669 (50.5)z
Office hypertension 311 (8.1) 120 (20.8)z 361 (36.3)z 2740 (83.0)z
On antihypertensive treatment 0 0 0 1899 (57.5)
Diabetes mellitus 157 (4.1) 31 (5.4) 61 (6.1)y 373 (11.3)z
Cardiovascular disorders 168 (4.4) 37 (6.4)M 59 (5.9)M 496 (15.0)z
Age (years) 48.515.1 54.915.2z 55.914.0z 61.711.9z
BMI (kg/m2) 24.43.7 25.44.2z 26.24.0z 26.64.5z
Conventional BP (mmHg)
Systolic 119.414.4 129.115.8z 134.915.7z 145.019.9z
Diastolic 74.19.0 78.99.2z 82.49.3z 86.111.9z
Ambulatory measurements
24-h SBP (mmHg) 113.87.4 124.26.8z 128.26.3z 135.214.2z
24-h DBP (mmHg) 68.45.0 75.15.1z 75.95.0z 79.29.1z
Daytime SBP (mmHg) 120.18.4 125.16.9z 139.87.8z 141.115.2z
Daytime DBP (mmHg) 73.55.8 76.65.8z 83.96.3z 83.910.0z
Daytime pulse rate (bpm) 78.610.0 78.310.3 79.210.4 76.411.2z
Night-time SBP (mmHg) 102.77.8 121.19.2z 109.36.8z 123.916.1z
Night-time DBP (mmHg) 59.35.4 71.86.1z 62.54.6z 70.69.9z
Night-time pulse rate (bpm) 63.39.0 65.610.7z 63.79.3 63.69.7
Serum cholesterol (mmol/l) 5.451.14 5.541.19z 5.871.16z 5.761.14z
Blood glucose (mmol/l) 4.950.98 5.301.69z 5.211.23z 5.541.68z
Data are means (SD) or number (%). Office hypertension was a conventional SBP of at least 140mmHg or DBP of 90mmHg, or use of antihypertensive drugs. Blood
glucose was available in 2905 normotensive individuals, 449 with isolated nocturnal hypertension, 855 with isolated daytime hypertension, and 2671 with sustained
hypertension. Differences among the four groups were significant (P<0.001) for all the characteristics. Significance of the difference with the normotensive reference
group: MP<0.05, yP<0.01, and zP<0.001. BP, blood pressure.
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stroke (hazard ratio 1.35, P¼ 0.13). The multivariable-
adjusted hazard ratios associated with sustained hyper-
tension (Table 3) were significant for total mortality
(1.51, P< 0.0001), cardiovascular mortality (2.19,
P< 0.0001), all cardiovascular events (2.48,
P< 0.0001), cardiac events (2.30, P< 0.0001), and stroke
(2.64, P< 0.0001). After exclusion of 1899 treated
patients from the sustained hypertensive group, the
hazard ratios for 1404 patients with elevated BP values
during day and night were 1.47 [95% confidence interval
(CI) 1.23–1.76, P< 0.0001) for total mortality, 2.16 (95%
CI 1.58–2.95, P< 0.0001) for cardiovascular mortality,
2.33 (95%CI 1.91–2.84,P< 0.0001) for all cardiovascular
events, 1.94 (95% CI 1.49–2.53, P< 0.0001) for cardiac
2040 Journal of Hypertension 2010, Vol 28 No 10
Table 2 Incidence of events by ambulatory blood pressure status
Normotension Isolated nocturnal hypertension Isolated daytime hypertension Sustained hypertension
Number of participants 3837 577 994 3303
All-causes mortality
Number of deaths 295 81 128 780
Crude rate 7.6 (6.7–8.4) 14.7 (11.5–17.9)z 12.4 (10.3–14.6)z 24.1 (22.4–25.8)z
Standardized rate 10.6 (5.9–15.3) 13.9 (2.2–25.6) 11.2 (3.3–19.1) 18.5 (11.6–25.4)
Cardiovascular mortality
Number of deaths 76 22 46 357
Crude rate 1.9 (1.5–2.4) 4.0 (2.6–5.7)y 4.5 (3.2–5.8)z 11.0 (9.9–12.2)z
Standardized rate 2.8 (0.7–4.9) 3.9 (0–8.7) 4.3 (0–9.0) 8.5 (4.1–12.8)
Noncardiovascular mortality
Number of deaths 210 55 76 401
Crude rate 5.4 (4.6–6.1) 10.0 (7.3–12.6)z 7.4 (5.7–9.1)M 12.4 (11.2–13.6)z
Standardized rate 7.5 (3.7–11.3) 9.3 (0.7–17.8) 6.5 (1.4–11.7) 9.2 (5.3–13.1)
All cardiovascular events
Number of events 188 54 112 755
Crude rate 4.9 (4.2–5.6) 10.1 (7.4–12.8)z 11.2 (9.2–13.3)z 25.1 (23.3–26.9)z
Standardized rate 7.0 (3.3–10.7) 9.7 (0.3–19.2) 11.1 (0.9–21.3) 20.1 (12.4–27.8)
Cardiac events
Number of events 108 31 73 406
Crude rate 2.8 (2.3–3.3) 5.7 (3.7–7.7)y 7.2 (5.6–8.9)z 13.0 (11.8–14.3)z
Standardized rate 4.0 (1.3–6.8) 5.6 (0–12.0) 6.5 (0.2–12.9) 10.7 (5.6–15.9)
Stroke
Number of strokes 78 20 39 344
Crude rate 2.0 (1.6–2.5) 3.7 (2.1–5.3)M 3.8 (2.6–5.0)y 11.0 (9.9–12.2)z
Standardized rate 2.7 (0.7–4.7) 3.4 (0–8.3) 4.4 (0–9.4) 8.5 (4.0–13.0)
Values are rates (95% confidence interval), expressed as number of events per 1000 person-years. Rates are crude or standardized for cohort, sex, and age (40, 40–60,
and 60 years) by the direct method. Significance of the difference with the normotensive reference group: MP<0.05, yP<0.01, and zP<0.001.
Fig. 1
Cumulative incidence of total mortality (a) and all cardiovascular events (b) by ambulatory blood pressure status. P values are for the differences
among the four categories by log-rank test.
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events, and 2.73 (95% CI 2.00–3.73, P< 0.0001) for
stroke.
Sensitivity analyses
Sensitivity analyses (Table 4) involving total mortality
and all cardiovascular events in relation to INH did not
show significant heterogeneity in the hazard ratios
(0.08P 0.89) according to baseline characteristics,
including ethnicity, sex, median age (<60 or 60 years),
BMI (<25 or25 kg/m2), current smoking (0, 1), drinking
alcohol (0, 1), or history of cardiovascular disease (0, 1).
The only exception was the risk of all cardiovascular
events associated with INH in smokers versus non-
smokers [hazard ratios (95% CI) 0.80 (0.43–1.47) versus
1.78 (95% 1.25–2.55), P¼ 0.016]. After further adjust-
ment for daytime SBP and DBP in addition to the
covariables we had considered in the multivariable Cox
models, INH still carried a higher risk for total mortality
[hazard ratio 1.28 (95% CI 1.00–1.64), P¼ 0.049] and for
all cardiovascular events [hazard ratio 1.34 (95% CI 0.99–
1.81), P¼ 0.06] compared with the normotensive group.
Similarly, after additional adjustment for night-time SBP
and DBP, IDH remained predictive for all cardiovascular
events [hazard ratio 1.39 (95% CI 1.10–1.77), P¼ 0.01],
but did not predict total mortality [hazard ratio 1.03 (95%
CI 0.84–1.28), P¼ 0.76].
Of 8711 participants, 5179 were normotensive on office
BP measurement and 4414 had daytime normotension on
ambulatory BP monitoring. Figure 2 shows the continu-
ous risk functions for total mortality and for all fatal and
nonfatal cardiovascular events associated with night-time
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Table 3 Hazard ratios by categories of ambulatory hypertension
Outcomes Isolated nocturnal hypertension Isolated daytime hypertension Sustained hypertension
All-causes mortality (1284) 81 128 780
Unadjusted 1.99 (1.56–2.55)z 1.67 (1.35–2.05)z 3.26 (2.85–3.73)z
Adjusted 1.29 (1.01–1.65)M 1.07 (0.86–1.32) 1.51 (1.31–1.74)z
Cardiovascular mortality (501) 22 46 357
Unadjusted 2.10 (1.31–3.38)y 2.32 (1.61–3.35)z 5.78 (4.51–7.40)z
Adjusted 1.30 (0.80–2.09) 1.38 (0.95–2.00) 2.19 (1.69–2.85)z
Noncardiovascular mortality (742) 55 76 401
Unadjusted 1.89 (1.41–2.55)z 1.38 (1.07–1.80)M 2.35 (1.98–2.77)z
Adjusted 1.23 (0.91–1.66) 0.90 (0.69–1.18) 1.19 (0.99–1.43)
All cardiovascular events (1109) 54 112 755
Unadjusted 2.08 (1.53–2.81)z 2.28 (1.81–2.89)z 5.16 (4.40–6.06)z
Adjusted 1.38 (1.02–1.87)M 1.46 (1.15–1.85)y 2.48 (2.10–2.94)z
Cardiac events (618) 31 73 406
Unadjusted 2.05 (1.38–3.06)z 2.56 (1.91–3.45)z 4.66 (3.77–5.76)z
Adjusted 1.41 (0.94–2.10) 1.53 (1.13–2.07)y 2.30 (1.84–2.88)z
Stroke (481) 20 39 344
Unadjusted 1.85 (1.13–3.02)y 1.90 (1.29–2.78)y 5.52 (4.32–7.06)z
Adjusted 1.21 (0.74–1.98) 1.35 (0.91–2.00) 2.64 (2.04–3.43)z
Hazard ratios (95% confidence intervals) express the risk relative to the normotensive group. Numbers of cases are given for each endpoint. The cause of death was
unknown in 41 cases. Cox models were adjusted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease and
diabetes mellitus. Significance of the hazard ratios: MP<0.05, yP<0.01, and zP<0.001.
Table 4 Adjusted hazard ratios associated with isolated nocturnal hypertension for total mortality and all cardiovascular events by baseline
characteristics
Total mortality All cardiovascular events
Stratification Events/at risk Hazard ratio (95% CI) Events/at risk Hazard ratio (95% CI)
All participants 1284/8711 1.29 (1.01–1.65)M 1109/8711 1.38 (1.02–1.87)M
European 830/5396 1.32 (0.96–1.82) 733/5396 1.34 (0.91–1.97)
Asian 358/1877 1.23 (0.79–1.92) 255/1877 1.37 (0.71–2.65)
South American 96/1438 0.91 (0.39–2.12) 121/1438 1.67 (0.76–3.67)
Women 411/4096 1.46 (0.93–2.29) 334/4096 1.70 (0.98–2.97)
Men 873/4615 1.21 (0.90–1.62) 775/4615 1.27 (0.88–1.83)
Age <60 years 177/4868 1.99 (1.14–3.47)M 190/4868 1.77 (0.89–3.55)
Age 60 years 1107/3843 1.17 (0.89–1.54) 919/3843 1.24 (0.89–1.75)
Smokers 452/2491 1.35 (0.91–2.00) 361/2491 0.80 (0.43–1.47)
Nonsmokers 832/6220 1.24 (0.90–1.71) 748/6220 1.78 (1.25–2.55)y
Drinkers 587/4126 1.13 (0.77–1.66) 531/4126 1.39 (0.89–2.19)
Nondrinkers 697/4585 1.37 (0.99–1.90) 578/4585 1.34 (0.88–2.03)
BMI <25 kg/m2 664/4366 1.26 (0.91–1.74) 505/4366 1.63 (1.08–2.46)M
BMI 25 kg/m2 620/4345 1.25 (0.85–1.84) 604/4345 1.12 (0.71–1.76)
Without CVD history 1040/7951 1.28 (0.98–1.67) 878/7951 1.27 (0.91–1.79)
With CVD history 244/760 1.57 (0.78–3.15) 231/760 2.09 (1.00–4.36)M
The hazard ratios (95%CIs) express the risk associatedwith isolated nocturnal hypertension relative to the normotensive group. For the covariates in the Coxmodels, please
see the legend of Table 3. Significance of the hazard ratios: MP<0.05, yP<0.01. Heterogeneity in the risk of all cardiovascular events between smokers and nonsmokers
was significant (P¼0.02). CI, confidence interval; CVD, cardiovascular disease.
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SBP and DBP in individuals with office or ambulatory
daytime normotension.
Of 457 patients with INH and normal office BP, 51
(11.2%) died and 38 (8.3%) experienced a composite
cardiovascular endpoint. Among 120 patients with both
INH and office hypertension, these numbers were 30
(25.0%) and 16 (13.3%), respectively. Although the rates
were higher among patients with both INH and office
hypertension compared with their counterparts with
office normotension, the hazard ratios associated with
INH remained significant for total mortality (1.31; 95%
CI 1.01–1.68, P¼ 0.039) and for all cardiovascular events
(1.38; 95% CI 1.01–1.87, P¼ 0.044) with additional
adjustment for the office BP. When we considered only
individuals with office normotension (n¼ 5179), the
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Fig. 2
Ten-year risk of total mortality (a and b) and of fatal and nonfatal combined cardiovascular events (c and d) associated with night-time SBP (left) and
DBP (right) in individuals with office normotension (full lines) or with ambulatory daytime normotension (dashed lines). In Cox regression models, the
incidence rates were adjusted for cohort, sex, age, BMI, smoking and drinking, serum cholesterol, history of cardiovascular disease, and diabetes
mellitus. No and Na indicate the number of events in individuals with office normotension and with ambulatory daytime normotension, respectively. Po
and Pa denote the corresponding significance of the independent contributions of night-time blood pressures.
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hazard ratios associated with INH were 1.17 (95% CI
0.86–1.59, P¼ 0.31) for total mortality and 1.48 (95% CI
1.03–2.12, P¼ 0.034) for all cardiovascular events.
Discussion
The key finding of our current meta-analysis based on
individual participant data was that while accounting for
age, sex, and other covariables, INHwas associated with a
significantly higher risk of total mortality and all cardio-
vascular events compared with normotensive individuals.
IDH predicted fatal and nonfatal cardiovascular and
cardiac events. Patients with sustained hypertension
carried a risk approximately twice as high for mortality
and all studied cardiovascular events compared with
the normotensive group. Our findings corroborated that
irrespective of the type of ambulatory hypertension, an
elevated BP is a major risk factor for cardiovascular
complications. INH, as well as IDH, are not benign
and carry a substantially increased risk versus normoten-
sion.
The unfavorable cardiovascular prognosis of INH was in
keeping with our previous report on the predictive values
of daytime and night-time BPs in the IDACO database,
which at the time of the publication [7] consisted of 7458
individuals from six populations. When night-time and
daytime BPs were analyzed as continuous variables,
night-time BP predicted all mortality outcomes, and all
cardiovascular, cardiac, and stroke events, independent of
the daytime BP and other covariables [7]. One SD
elevation of the night-time SBP and DBP increased
cardiovascular risk by approximately 20%. Daytime BP
did not independently predict mortality outcomes, and
was only associated with cardiovascular, coronary, and
stroke events [7].
Previous studies in hypertensive patients [25–29] as well
as in populations [13,17,30] demonstrated that an elev-
ated nocturnal BP or a diminished nocturnal BP fall was
associated with a worse outcome. In 1542 Ohasama
residents [13], each 5% decrease in the nocturnal SBP
or DBP fall was associated with an approximately 20%
greater risk of cardiovascular mortality. Even when 24-h
BP values were within the normal range (defined as
<135/80mmHg), a diminished nocturnal BP reduction
was associated with an increased risk of cardiovascular
mortality. In a recently published meta-analysis [28] of
individual data of 3468 hypertensive patients from four
European studies, both daytime and night-time BP pre-
dicted all-cause and cardiovascular mortality, coronary
heart disease, and stroke. However, when night-time and
daytime BPs were added to the same Cox model, the
night-time BP predicted all outcomes, whereas daytime
BP did not add prognostic precision to the night-time
pressure. That the night-time BP was superior to the
daytime BP in the prediction of mortality outcomes was
also reported in the patients randomized to placebo in the
double-blind Systolic Hypertension in Europe trial [25],
in Irish hypertensive patients [26], and in a recent
Ohasama publication [30].
INH is a heterogeneous disorder, only characterized by
an elevation of BP at night in the presence of a normal
daytime BP. In the current study, 20.8% of patients with
INH had office hypertension. Two other studies also
reported on INH, but determined daytime normotension
either by the use of office BP [3] or the self-measured BP
at home [2]. The prevalence of INH was 7.2% in middle-
aged patients with type 2 diabetes and close to 30% in the
subgroup of diabetic patients with office normotension
[3]. Irrespective of its definition, INHwas associated with
increased pulse wave velocity [1,3], higher central BP [3]
and increased systolic augmentation [1], increased carotid
intima–medial thickness, left ventricular remodeling, or
all [2]. Our current results, for the first time, established
the prognostic implications of INH in terms of mortality
and morbidity.
The mechanisms linking INH with a worse cardiovas-
cular outcome remain to be elucidated. Several mechan-
isms might be involved, such as excess sympathetic
activation [31], disturbed baroreflex sensitivity or auto-
nomic failure [32,33], decreased daytime sodium
excretion [34], nocturnal pressure natriuresis [35],
increased nocturnal activity [36], sleep apnea [37], insulin
resistance [38], impaired endothelial function, or all [39].
Furthermore, as noticed in our current study and in
previous reports [1–3], patients with INH were more
likely to be older, to have diabetes, or a history of
cardiovascular disease. Clustering of cardiovascular risk
factors might, therefore, also contribute to the worse
prognosis associated with INH.
The current study has to be interpreted within the
context of its potential limitations. First, although our
total sample size was over 8000, we had only 577 patients
with INH and relatively few events in this group. The
statistical power was low for specific cardiovascular out-
comes, for instance, we had only 42 and 12% power to
reject the null hypothesis of no association for cardiac
events and stroke, respectively. Second, the reproduci-
bility of INH is low. In a follow-up study [1] of the
JingNing cohort, at a median interval of 3.5 years, one-
third of the patients with INH at baseline kept this
condition; one-third developed sustained hypertension,
whereas others shifted to normotension or IDH.
Our current findings might have implications for clinical
practice. INH can only be diagnosed by automated
measurement of BP during sleep. Ambulatory BP
monitoring is the best technique to obtain the night-time
measurements in an identical way as those during day-
time. Our study adds to the growing evidence that
ambulatory BP monitoring should be applied more
widely in clinical practice [40], and highlights the import-
ance of having BPmonitored during the whole day, rather
than during a limited time window. Further studies are
Prognosis of isolated nocturnal hypertension Fan et al. 2043
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needed to address the benefit of specifically lowering the
night-time BP in patients with INH.
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